The World Health Organization on Tuesday identified a new COVID-19 “variant of interest” making up an increasing share of COVID-19 cases worldwide. The variant, JN.1, was first identified in August and now comprises an estimated 27.1% of COVID cases worldwide, according to the WHO.
JN.1 was first detected in the U.S. in September and, even by the end of October, it made up less than 0.1% of COVID-19 cases, according to the U.S. Centers for Disease Control. That percentage jumped dramatically in November and, in the most recent data for the two-week period ending Dec. 9, JN.1 accounted for between 15% and 29% of currently circulating variants.
That does not mean, however, that JN.1 is causing more severe symptoms than other variants.
“At this time, there is no evidence that JN.1 presents an increased risk to public health relative to other currently circulating variants,” said the CDC on Dec. 8. “There is no indication of increased severity from JN.1 at this time.”
JN.1 is nearly identical to the Omicron subvariant BA.2.86 but contains a spike protein mutation that may make it more effective in penetrating the immune system.
A rapidly spreading new variant is not, in itself, cause for concern among the general public, said Amesh Adalja, Senior Scholar at the Johns Hopkins Center for Health Security and a Pittsburgh-based infectious disease physician. “In general, I think that the public doesn’t really need to keep track of the names of every variant that appears,” he said. “There’s always going to be a new variant rising, an older variant falling, multiple variants circulating — that’s just how evolution works.”
Generally, the population is better equipped to handle new variants than it was when the Delta and Omicron variants first debuted and sent hospital admissions soaring.
Most of the population has at least some level of immunity, either through prior infections, vaccinations or both. And the drug Paxlovid is “variant agnostic,” said Dr. Adalja, meaning that it works even on new variants. The latest COVID vaccine should offer some protection against the new variant, he said, recommending that high-risk people take advantage of the updated vaccines.
“Its ability to cause severe disease is going to be hampered by all the immunity,” he said. “This is very different from the population it encountered in 2019.”
While there is no indication that JN.1 is more severe than other variants, there is the possibility that a rapidly spreading new variant will result in increased cases on the whole. “It is anticipated that this variant may cause an increase in SARS-CoV-2 cases amid [sic] surge of infections of other viral and bacterial infections, especially in countries entering the winter season,” cautioned the WHO.
Allegheny County has seen increases in respiratory virus cases and, on Wednesday, UPMC reinstated mask requirements for patients and staff due to the prevalence of those viruses, including COVID-19, flu and RSV.
When UPMC announced the change last week, CDC data showed a 42% increase in COVID-19 hospital admissions in Allegheny County for the week ending Dec. 2 from the week prior. For the week ending Dec. 9, cases fell 17.8% from the previous week, with 152 people hospitalized.
Allegheny County is still considered to be at a “low” level for COVID-19 hospitalizations. Its rate of hospital admissions is 7.4 per 100,000 population; anything below 10 per 100,000 population is considered low.
Anya Sostek: asostek@post-gazette.com





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.